CoChat
Sign Up
Cited by 428Barrier Structure and Function StudiesDrug Transport and Resistance MechanismsNanoparticle-Based Drug Delivery

The DOI matches its Crossref record.

Osmotic Opening of the Blood–Brain Barrier: Principles, Mechanism, and Therapeutic Applications

Open access
Rapoport, Stanley I.·2000·Cellular and Molecular Neurobiology
DOI 10.1023/a:1007049806660PMC PMC11537517
Open this paper in CoChat — free account

Abstract

1. Osmotic opening of the blood-brain barrier by intracarotid infusion of a hypertonic arabinose or mannitol solution is mediated by vasodilatation and shrinkage of cerebrovascular endothelial cells, with widening of the interendothelial tight junctions to an estimated radius of 200 A. The effect may be facilitated by calcium-mediated contraction of the endothelial cytoskeleton. 2. The marked increase in apparent blood-brain barrier permeability to intravascular substances (10-fold for small molecules) following the osmotic procedure is due to both increased diffusion and bulk fluid flow across the tight junctions. The permeability effect is largely reversed within 10 min. 3. In experimental animals, the osmotic method has been used to grant wide access to the brain of water-soluble drugs, peptides, antibodies, boron compounds for neutron capture therapy, and viral vectors for gene therapy. The method also has been used together with anticancer drugs to treat patients with metastatic or primary brain tumors, with some success and minimal morbidity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1023/a:1007049806660

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Temporal opening of the BBB can be achieved with transient uprise of osmotic pressure or physically with FUS.

    “Temporal opening of the BBB can be achieved with transient uprise of osmotic pressure (491) or physically with FUS (84)”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [491]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Still being checked.

Research works printed but not linked: 98

  1. Abbott, N. J., and Revest, P. A. (1991). Control of brain endothelial permeability. Cerebrovasc. Brain Metab. Rev. 3:39-72.
  2. Armstrong, B. K., Robinson, P. J., and Rapoport, S. I. (1987). Size-dependent blood-brain barrier opening demonstrated with [14C]sucrose and a 200,000-Da [3H]dextran. Exp. Neurol. 97:686-696. · DOI
  3. Armstrong, B. K., Smith, Q. R., Rapoport, S. I., Strohalm, J., Kopecek, J., and Duncan, R. (1989). Osmotic opening of the blood-brain barrier permeability to n-(2-hydroxypropyl) methacrylamide copolymers. Effect of polymer Mw, charge and hydrophobicity. J. Control. Release 10:27-35. · DOI
  4. Barranger, J. A., Rapoport, S. I., Fredericks, W. R., Pentchev, P. G., MacDermot, K. D., Steusing, J. K., and Brady, R. O. (1979). Modification of the blood-brain barrier: Increased concentration and fate of enzymes entering the brain. Proc. Natl. Acad. Sci. USA 76:481-485. · DOI
  5. Barth, R. F., Yang, W., Rotaru, J. H., Moeschberger, M. L., Joel, D. D., Nawrocky, M. H., Goodman, J. H., and Soloway, A. H. (1997). Boron neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res. 57:1129-1136.
  6. Brightman, M. W., Hori, M., Rapoport, S. I., Reese, T. S., and Westergaard, E. (1973). Osmotic opening of tight junctions in cerebral endothelium. J. Comp. Neurol. 152:317-325. · DOI
  7. Brownson, E. A., Abbruscato, T. J., Gillespie, T. J., Hruby, V. J., and Davis, T. P. (1994). Effect of peptidases at the blood brain barrier on the permeability of enkephalin. J. Pharmacol. Exp. Ther. 270:675-680. · DOI
  8. Chamberlain, M. C., Murovic, J. S., and Levin, V. A. (1988). Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 38:1371-1374. · DOI
  9. Chi, O. Z., Lu, X., Wei, H. M., Williams, J. A., and Weiss, H. R. (1996). Hydroxyethyl starch solution attenuates blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. Anesth. Analg. 83:336-341. · DOI
  10. Chi, O. Z., Chang, Q., Wang, G., and Weiss, H. R. (1997). Effects of nitric oxide on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats. Anesth. Analg. 84:370-375. · DOI
  11. Chiueh, C. C., Sun, C. L., Kopin, I. J., Fredericks, W. R., and Rapoport, S. I. (1978). Entry of [3H]norepinephrine, [125I]albumin and Evans blue from blood into brain following unilateral osmotic opening of the blood-brain barrier. Brain Res. 145:292-301. · DOI
  12. Collander, R. (1937). The permeability of plant protoplasts to non-electrolytes. Trans. Faraday Soc. 33:985-990. · DOI
  13. Cosolo, W. C., Martinello, P., Louis, W. J., and Christophidis, N. (1989). Blood-brain barrier disruption using mannitol: Time course and electron microscopic studies. Am. J. Physiol. 256:R443-R447.
  14. Crossen, J. R., Goldman, D. L., Dahlborg, S. A., and Neuwelt, E. A. (1992). Neuropsychological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy. Neurosurgery 30:23-29. · DOI
  15. Dahlborg, S. A., Henner, W. D., Crossen, J. R., Tableman, M., Petrillo, A., Braziel, R., and Neuwelt, E. A. (1996). Non-AIDS primary CNS lymphoma: The first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J. Sci. Am. 2:166-174.
  16. DeAngelis, L. M. (1993). Cerebral lymphoma presenting as a nonenhancing lesion on a computed tomographic/magnetic resonance scan. Ann. Neurol. 33:308-311. · DOI
  17. Dehouck, B., Fenart, L., Dehouck, M.-P., Pierce, A., Torpier, G., and Cecchelli, R. (1997). A new function of the LDL receptor: Transcytosis of LDL through blood-brain barrier. J. Cell Biol. 138:877-889. · DOI · Paper page
  18. Dorovini-Zis, K., Sato, M., Goping, G., Rapoport, S. I., and Brightman, M. (1983). Ionic lanthanum passage across cerebral endothelium exposed to hyperosmotic arabinose. Acta Neuropathol. (Berlin) 60:49-60. · DOI
  19. Dorovini-Zis, K., Bowman, P. D., Betz, A. L., and Goldstein, G. W. (1984). Hyperosmotic arabinose solutions open tight junctions between brain capillary endothelial cells in tissue culture. Brain Res. 302:383-386. · DOI
  20. Fenstermacher, J. D., and Johnson, J. A. (1966). Filtration and reflection coefficients of the rabbit bloodbrain barrier. Am. J. Physiol. 211:341-346. · DOI
  21. Fishman, J. B., Rubin, J., Handrahan, J. V., Connor, J. R., and Fine, R. E. (1987). Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 18:299-304. · DOI
  22. Friden, P. M., Walus, L. R., Musso, G. F., Taylor, M. A., Malfroy, B., and Starzyk, R. M. (1991). Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Sci. USA 88:4771-4775. · DOI
  23. Friden, P. M., Walus, L. R., Watson, P., Doctrow, S. R., Kozarich, J. W., Bäckman, C., Bergman, H., Hoffer, B., Bloom, F., and Granholm, A.-C. (1993). Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 259:373-377. · DOI
  24. Gjedde, A., Reith, J., Léger, G., Cumming, P., Yasuhara, Y., Guttman, M., and Kuwabara, H. (1995). Blood-brain barrier removal of DOPA: Role in regulation of dopamine synthesis and treatment of Parkinson's disease. In Greenwood, J., Begley, D., and Segal, M. (eds.), New Concepts of a Blood-Brain Barrier, Plenum Press, London, pp. 103-109. · DOI
  25. Greig, N. H., Fredericks, W. R., Holloway, H. W., Soncrant, T. T., and Rapoport, S. I. (1988). Delivery of interferon-alpha to brain by transient osmotic blood-brain barrier modification in the rat. J. Pharmacol. Exp. Ther. 245:581-586. · DOI
  26. Gumbiner, B. M. (1996). Cell adhesion: The molecular basis of tissue architecture and morphogenesis. Cell 84:345-357. · DOI · Paper page
  27. Gumerlock, M. K., and Neuwelt, E. A. (1990). The effects of anesthesia on osmotic blood-brain barrier disruption. Neurosurgery 26:268-277. · DOI
  28. Gumerlock, M. K., Belshe, B. D., Madsen, R., and Watts, C. (1992). Osmotic blood-brain barrier disruption and chemotherapy in the treatment of high grade malignant glioma: Patient series and literature review. J. Neurooncol. 12:33-46. · DOI
  29. Gumerlock, M. K., York, D., and Durkis, D. (1994). Visual evoked responses as a monitor of intracranial pressure during hyperosmolar blood-brain barrier disruption. Acta Neurochir. Suppl. 60:132-135.
  30. Hicks, J. T., Albrecht, P., and Rapoport, S. I. (1976). Entry of neutralizing antibody to measles into brain and cerebrospinal fluid of immunised momkeys following osmotic opening of the blood-brain barrier. Exp. Neurol. 53:768-779. · DOI
  31. Hiesiger, E. M., Voorhies, R. M., Basler, G. A., Lipscuhtz, L. E., Posner, J. B., and Shapiro, W. R. (1986). Opening the blood-brain and blood-tumor barriers in experimental rat brain tumor: the effect of intracarotid hyperosmolar mannitol on capillary permeability and blood flow. Ann. Neurol. 19:50-59. · DOI
  32. Inamura, T., Nomura, T., Bartus, R. T., and Black, K. L. (1994). Intracarotid infusion of RMP-7, a bradykinin analog: A method for selective drug delivery to brain tumors. J. Neurosurg. 81:752-758. · DOI
  33. Jena, M., Minore, J. F., and O'Neill, W. C. (1997). A volume-sensitive, IP3-insensitive Ca2+ store in vascular endothelial cells. Am. J. Physiol. 273:C316-C322. · DOI
  34. Jiao, S., Miller, P. J., and Lapchak, P. A. (1996). Enhanced delivery of [125I]glial cell line-derived neurotrophic factor to the rat CNS following osmotic blood-brain barrier modification. Neurosci. Lett. 220:187-190. · DOI
  35. Kessler, R. M., Goble, J. C., Bird, J. H., Girton, M. E., Doppman, J. L., Rapoport, S. L., and Barranger, J. A. (1984). Measurement of blood-brain barrier permeability with positron emission tomography and [68Ga]EDTA. J. Cereb. Blood Flow Metab. 4:323-328. · DOI
  36. Latker, C. H., Lynch, K. J., Shinowara, N. L., and Rapoport, S. I. (1986). The morphology of pial blood vessels of the frog, preserved by rapid freezing and freeze substitution. Brain Res. 375:186-192. · DOI
  37. Levine, R. L., Fredericks, W. R., and Rapoport, S. I. (1985). Clearance of bilirubin from rat brain after reversible osmotic opening of the blood-brain barrier. Pediatr. Res. 19:1040-1043. · DOI
  38. Lin, W. L. (1988). Leakage of blood-retinal barrier due to damaging effect of protamine sulfate on the endothelium. Acta Neuropathol. (Berl.) 76:427-431. · DOI
  39. Lin, W., Paczynski, R. P., Kuppusamy, K., Hsu, C. Y., and Haacke, E. M. (1997). Quantitative measurements of regional cerebral blood volume using MRI in rats: effects of arterial carbon dioxide tension and mannitol. Magn. Reson. Med. 38:420-428. · DOI
  40. Lowenstein, P. R., Morrison, E. E., Bain, D., Hodge, P., Preston, C. M., Clissold, P., Stow, N. D., Mckee, T. A., and Castro, M. G. (1994). Use of recombinant vectors derived from herpes simplex virus 1 mutant tsK for short-term expression of transgenes encoding cytoplasmic and membrane anchored proteins in postmitotic polarized cortical neurons and glial cells in vitro. Neuroscience 60:1059-1077. · DOI
  41. Millay, R. H., Klein, M. L., Shults, W. T., Dahlborg, S. A., and Neuwelt, E. A. (1986). Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier. Am. J. Ophthalmol. 102:626-632. · DOI
  42. Muldoon, L. L., Nilaver, G., Kroll, R. A., Pagel, M. A., Breakefield, X. O., Chiocca, E. A., Davidson, B. L., Weissleder, R., and Neuwelt, E. A. (1995). Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am. J. Pathol. 147:1840-1851.
  43. Nag, S. (1995). Role of the endothelial cytoskeleton in blood-brain barrier permeability to protein. Acta Neuropathol. (Berl.) 90:454-460. · DOI
  44. Nagashima, T., Shijing, W., Mizoguchi, A., and Tamaki, N. (1994). A possible role of calcium ion in osmotic opening of blood-brain barrier. J. Auton. Nerv. Syst. 49 (Suppl.):S145-S149. · DOI
  45. Neuwelt, E. A., Frenkel, E. P., Diehl, J., Vu, L. H., Rapoport, S. I., and Hill, S. A. (1980). Reversible osmotic blood-brain barrier disruption in humans: Implication for the chemotherapy of malignant brain tumors, Neurosurgery 7:44-52. · DOI
  46. Neuwelt, E. A., Glasberg, M., Frenkel, E., and Barnett, P. (1983). Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: Neuropathological studies. Ann. Neurol. 14:316-324. · DOI
  47. Neuwelt, E. A., Barnett, P. A., Hellstrom, I., Hellstrom, K. E., Beaumier, P., McCormick, C. I., and Weigel, R. M. (1988). Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res. 48:4725-4729.
  48. Neuwelt, E. A., Dahlborg, S. A., Goldman, D., Dana, B., and Ramsey, F. L. (1989). Significant prolongation of survival of primary CNS lymphoma patients by combination chemotherapy given in association with osmotic blood-brain barrier disruption. Proc. Am. Assoc. Cancer Res. 30:264.
  49. Neuwelt, E. A., Williams, P. C., Mickey, B. E., Frenkel, E. P., and Henner, W. D. (1994). Therapeutic dilemma of disseminated CNS germinoma and the potential of increased platinum-based chemotherapy delivery with osmotic blood-brain barrier disruption. Pediatr. Neurosurg. 21:16-22. · DOI
  50. Neuwelt, E. A., Brummett, R. E., Remsen, L. G., Kroll, R. A., Pagel, M. A., McCormick, C. I., Guitjens, S., and Muldoon, L. L. (1996). In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res. 56:706-709.
  51. Ohata, M., Fredericks, W. R., Neuwelt, E. A., Sundaram, U., and Rapoport, S. I. (1985). [3H]Methotrexate loss from the rat brain following enhanced uptake by osmotic opening of the blood-brain barrier. Cancer Res. 45:1092-1096.
  52. Ohno, K., Pettigrew, K. D., and Rapoport, S. I. (1978). Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am. J. Physiol. 235:H299-H307.
  53. Oike, M., Droogmans, G., and Nilius, B. (1994). Mechanosensitive Ca2+ transients in endothelial cells from human umbilical vein. Proc. Natl. Acad. Sci. USA 91:2940-2944. · DOI
  54. Okisaka, S., Kuwabara, T., and Rapoport, S. I. (1974). Selective destruction of the pigmented epithelium in the ciliary body of the eye. Science 184:1298-1299. · DOI
  55. Olesen, S. P. (1987). Regulation of ion permeability in frog brain venules. Significance of calcium, cyclic nucleotides and protein kinase C. J. Physiol. (Lond.) 387:59-69. · DOI
  56. Overton, E. (1895). Ñber die osmotischen Eigenschaften der lebenden Pflanzen und Tierzelle. Vierteljahresschr. Naturforsch. Ges. Zurich 40:159-201.
  57. Pastan, I., Willingham, M. C., and Gottesman, M. (1991). Molecular manipulations of the multidrug transporter: A new role for transgenic mice. FASEB J. 5:2523-2528. · DOI
  58. Rapoport, S. I. (1970). Effect of concentrated solutions on blood-brain barrier. Am. J. Physiol. 219:270-274. · DOI
  59. Rapoport, S. I. (1976). Blood-Brain Barrier in Physiology and Medicine, Raven Press, New York, p. 316.
  60. Rapoport, S. I. (1988). Osmotic opening of the blood-brain barrier. Ann. Neurol. 24:677-680. · DOI
  61. Rapoport, S. I. (1991). Microinfarction: Osmotic BBB opening of microcrystals in infusate? J. Neurosurg. 74:685.
  62. Rapoport, S. I. (1996). Modulation of blood-brain barrier permeability. J. Drug Target. 3:417-425. · DOI
  63. Rapoport, S. I. (1997). Brain edema and the blood-brain barrier. In Welch, K. M. A., Caplan, L. R., Reis, D. J., Siesjö, B. K., and Weir, B. (eds.), Primer on Cerebrovascular Diseases, Academic Press, New York, pp. 25-28. · DOI
  64. Rapoport, S. I., and Robinson, P. J. (1986). Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier. Ann. N.Y. Acad. Sci. 481:250-267. · DOI
  65. Rapoport, S. I., and Robinson, P. J. (1990). A therapeutic role for osmotic opening of the blood-brain barrier. Re-evaluation of literature and of importance of source-sink relations between brain and tumor. In Johanson, B. B., Owman, C., and Widner, H. (eds.), Pathophysiology of the Blood-Brain Barrier, Long Term Consequences of Barrier Dysfunction for the Brain, Elsevier, Amsterdam, pp. 167-181.
  66. Rapoport, S. I., and Thompson, H. K. (1973). Osmotic opening of the blood-brain barrier in the monkey without associated neurological deficits. Science 180:971. · DOI
  67. Rapoport, S. I., Hori, M., and Klatzo, I. (1972). Testing of a hypothesis for osmotic opening of the blood-brain barrier. Am. J. Physiol. 223:323-331. · DOI
  68. Rapoport, S. I., Fredericks, W. R., Ohno, K., and Pettigrew, K. D. (1980). Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am. J. Physiol. 238:R421-R431.
  69. Rapoport, S. I., Fitzhugh, R., Pettigrew, K. D., Sundaram, U., and Ohno, K. (1982). Drug entry into and distribution within brain and cerebrospinal fluid: 14C-Urea pharmacokinetics. Am. J. Physiol. 242:R339-R348. · DOI
  70. Ravussin, P., Archer, D. P., Tyler, J. L., Meyer, E., Abou-Madi, M., Diksic, M., Yamamoto, L., and Trop, D. (1986). Effects of rapid mannitol infusion on cerebral blood volume. A positron emission tomographic study in dogs and man. J. Neurosurg. 64:104-113. · DOI
  71. Reese, T. S., and Karnovsky, M. J. (1967). Fine structural localization of a blood-brain barrier to exogenous peroxidase. J. Cell Biol. 34:207-217. · DOI · Paper page
  72. Robinson, P. J., and Rapoport, S. I. (1987). Size selectivity of blood-brain barrier permeability at various times after osmotic opening. Am. J. Physiol. 253:R459-R466.
  73. Robinson, P. J., and Rapoport, S. I. (1990). Model for drug uptake by brain tumors: Effects of osmotic treatment and of diffusion in brain. J. Cereb. Blood Flow Metab. 10:153-161. · DOI
  74. Rosomoff, H. L. (1962). Distribution of intracranial contents after hypertonic urea. J. Neurosurg. 19:859-864. · DOI
  75. Salahuddin, T. S., Johansson, B. B., Kalimo, H., and Olsson, Y. (1988). Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study. Acta Neuropathol. (Berl.) 77:5-13. · DOI
  76. Sanovich, E., Bartus, R. T., Friden, P. M., Dean, R. L., Le, H. Q., and Brightman, M. (1995). Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res. 705:125-135. · DOI
  77. Schinkel, A. H., Smit, J. J., van Telligen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., De Riele, H. P. J., Berns, A. J. M., and Borst, P. (1994). Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502. · DOI
  78. Smith, Q. R. (1993). Drug delivery to brain and the role of carrier-mediated transport. Adv. Exp. Med. Biol. 331:83-93. · DOI
  79. Staddon, J. M., and Rubin, L. L. (1996). Cell adhesion, cell junctions and the blood-brain barrier. Curr. Opin. Neurobiol. 6:622-627. · DOI
  80. Suzuki, M., Iwasaki, Y., Yamamoto, T., Konno, H., and Kudo, H. (1988). Sequelae of the osmotic bloodbrain barrier opening in rats. J. Neurosurg. 69:421-428. · DOI
  81. Takada, T., Vistica, D. T., Greig, N. H., Purdon, D., Rapoport, S. I., and Smith, Q. R. (1992). Rapid high-affinity transport of a chemotherapeutic amino acid across the blood-brain barrier. Cancer Res. 52:2191-2196.
  82. Takahashi, M., Tsutsui, H., Murayama, C., Miyazawa, T., and Fritz-Zieroth, B. (1996). Neurotoxicity of gadolinium contrast agents for magnetic resonance imaging in rats with osmotically disrupted blood-brain barrier. Magn. Reson. Imaging 14:619-623. · DOI
  83. Tator, C. H. (1972). Chemotherapy of brain tumors: uptake of tritiated methotrexate by a transplantable intracerebral ependymoblastoma in mice. J. Neurosurg. 37:1-8. · DOI
  84. Tomiwa, K., Hazama, F., and Mikawa, H., (1982). Reversible osmotic opening of the blood-brain barrier: Prevention of tissue damage with filtration of the perfusate. Acta Pathol. Jpn. 32:427-435.
  85. Tomiwa, K., Hazama, F., and Mikawa, H. (1983). Neurotoxicity of vincristine after the osmotic opening of the blood-brain barrier. Neuropathol. Appl. Neurobiol. 9:345-354. · DOI
  86. Walker, M. (1977). Treatment of brain tumors. Med. Clin. North Am. 61:1045-1051. · DOI
  87. Warnke, P. C., Blasberg, R. G., and Groothuis, D. R. (1987). The effect of hyperosmotic blood-brain barrier disruption on blood-to-tissue transport in ENU-induced gliomas. Ann. Neurol. 22:300-305. · DOI
  88. Westergren, I., and Johansson, B. B. (1993). Altering the blood-brain barrier in the rat by intracarotid infusion of polycations: A comparison between protamine, poly-L-lysine and poly-L-arginine. Acta Physiol. Scand. 149:99-104. · DOI
  89. Wielbo, D., Sernia, C., Gyurko, R., and Phillips, M. I. (1995). Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension 25:314-319. · DOI
  90. Williams, P. C., Henner, W. D., Roman-Goldstein, S., Dahlborg, S. A., Brummett, R. E., Tableman, M., Dana, B. W., and Neuwelt, E. A. (1995). Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 37:17-28. · DOI
  91. Williams, W. M., Chang, M. C., and Rapoport, S. I. (1994). Cerebral microvessel phospholipase A2 activity in senescent mouse. Neurochem. Res. 19:317-320. · DOI
  92. Wong, A. J., and Gotleib, A. I. (1986). Endothelial cell monolayer integrity. I. Characterization of dense peripheral band of microfilaments. Arteriosclerosis 6:212-219. · DOI
  93. Yang, W., Barth, R. F., Carpenter, D. P., Moeschberger, M. L., and Goodman, J. H. (1996). Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption. Neurosurgery 38:965-992. · DOI
  94. Ziylan, Y. Z., Robinson, P. J., and Rapoport, S. I. (1983). Differential blood-brain barrier permeabilities to 14C-sucrose and 3H-inulin after osmotic opening in the rat. Exp. Neurol. 79:845-857. · DOI
  95. Ziylan, Y. Z., Robinson, P. J., and Rapoport, S. I. (1984). Blood-brain barrier permeability to sucrose and dextran after osmotic opening. Am. J. Physiol. 247:R634-R638.
  96. Zlokovic, B. V., and Apuzzo, M. L. J. (1997). Cellular and molecular neurosurgery: Pathways from concept to reality-Part II: Vector systems and delivery methodologies for gene therapy of the central nervous system. Neurosurgery 40:805-813. · DOI
  97. Zunkeler, B., Carson, R. E., Olson, J., Blasberg, R. G., Girton, M., Bacher, J., Herscovitch, P., and Oldfield, E. H. (1996a). Hyperosmolar blood-brain barrier disruption in baboons: An in vivo study using positron emission tomography and rubidium-82. J. Neurosurg. 84:494-502. · DOI
  98. Zunkeler, B., Carson, R. E., Olson, J., Blasberg, R. G., DeVroom, H., Lutz, R. J., Saris, S. C., Wright, D. C., Kammerer, W., Patronas, N. J., Dedrick, R. L., Herscovitch, P., and Oldfield, E. H. (1996b). Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J. Neurosurg. 85:1056-1065. · DOI

Cited by

Sorted by citations

Metadata

Authors
Rapoport, S. I.
Affiliations
National Institutes of Health (US)
Corresponding author
Rapoport, Stanley I.
Venue
Cellular and Molecular Neurobiology
Publisher
Springer Science and Business Media LLC
Published
2000-04
Volume
20
Issue
2
Pages
217-230
ISSN
  • 0272-4340 (ISSN-L)
  • 1573-6830
DOI
10.1023/a:1007049806660
PMC
PMC11537517
OpenAlex
W107883495
Cited by
428
References
0
Citations by year
2026: 17 · 2025: 12 · 2024: 25 · 2023: 21 · 2022: 18 · 2021: 35 · 2020: 25 · 2019: 28 · 2018: 13 · 2017: 11 · 2016: 20 · 2015: 15 · 2014: 13 · 2013: 18 · 2012: 11
FWCI
5.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Cellular and Molecular Neurobiology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
blood-brain barrier, mannitol, intracarotid infusion, brain endothelial cells, tight junctions, vasodilation, endothelial cytoskeleton, blood-brain barrier permeability, brain drug delivery, gene therapy vectors, neutron capture therapy, brain tumors, brain metastases, anticancer agents
MeSH terms
Animals, Arabinose, Blood-Brain Barrier, Carotid Arteries, Cerebrovascular Circulation, Endothelium, Vascular, Humans, Hypertonic Solutions, Infusions, Intra-Arterial, Mannitol

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review